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Abstract
Behavioural and psychological symptoms of dementia (BPSD) are present in the
course of the illness in up to 90% of patients with Alzheimer's disease (AD).
They are the main source of caregiver burden and one of the major factors
contributing to early institutionalization. The involvement of a genetic component
in BPSD aetiology seems beyond controversy, though the exact significance of
particular polymorphisms is uncertain in the majority of cases. Multiple genes
have been assessed for their putative influence on BPSD risk. In this paper we
review the behavioural genetics of AD, particularly the importance, with respect
to BPSD risk, of genes coding for apolipoprotein E and proteins involved in the
process of neurotransmission: serotonin receptors, serotonin transporter, COMT,
MAO-A, tryptophan hydroxylase and dopamine receptors. A general conclusion
is the striking inconsistency of the findings, unsurprising in the field of
psychiatric genetics. The potential reasons for such discrepancy are exhaustively
discussed.
Key words: Alzheimer’s disease, behavioural disturbances, behavioural and
psychological symptoms of dementia, genetics, polymorphisms.
Introduction
Dementing disorders can usually be characterized by impairments in
cognition and behaviour with resulting subsequent decline in activities of
daily living (ADL). In the more advanced stages cognitive function
disturbances are usually accompanied by mood disorders, anxiety, apathy,
dysphoria, psychotic symptoms (delusions, hallucinations), aggression or
agitation. These symptoms, alongside other behavioural disturbances
(wandering, inappropriate sexual behaviours), are often clustered together
as behavioural and psychological symptoms of dementia (BPSD). In the
course of the illness BPSD can be present in as many as 60-98% of
demented individuals, with an average of around 80% in subjects with
Alzheimer's disease (AD) [1]. The presence of BPSD, as an exponent of the
more aggressive disease course, is usually followed by particularly
significant prognostic implications: a more rapid decline in both cognitive
functions and ADL [2], increased mortality [3] as well as early
institutionalization of individuals with AD [4]. The dramatic functional
decline of the patients leading to autonomy loss and rapidly progressive
caregiver dependence is much more a consequence of peracute psychiatric
pathology rather than cognitive impairment per se. The presence of BPSD
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and consequently the patient’s lack of self-
containment are also the main sources of caregiver
burden and major contributors to the increased
prevalence of depression in this population [5]. In
the context of the clinical, economical and social
significance of BPSD, discovering mechanisms
implicated in their pathogenesis is among the top-
priority challenges of modern old-age psychiatry.
However, our knowledge on the aetiology of these
symptoms is still incomplete. Behavioural and
psychological symptoms of dementia have been
hypothesized to be caused by unmet needs (for
example, needs for social contact, activity, relief of
pain, or hunger), by the inability of the patient to
communicate those needs, and by the inability of
the environment to meet those needs [6]. Biological
theories have focused on the role of various
neurotransmitter systems, including serotonin 
[5-HT] (aggression, depression, anxiety, psychosis)
[7], dopamine [DA] (aggression, psychosis) [8],
norepinephrine [NA] (aggression) [9], acetylcholine
[ACh] (psychosis, apathy) [10] and γ-aminobutyric
acid [GABA] [11]. Neurochemical BPSD theories have
led to pharmacological treatments targeting specific
neurotransmitters [12]. A wealth of evidence
(although conflicting at times) associates
behavioural symptoms with the progression of
neuropathological changes [13], abnormalities seen
in neuroimaging procedures [14], or the results of
electrophysiological studies [15]. Furthermore, there
are accruing data on the association between
genetic factors and behavioural abnormalities in
AD. In this paper we review the available evidence
on the behavioural genetics of AD. 
Behavioural genetics of Alzheimer’s disease
One of the most popular hypotheses regarding
genetic risk factors states that common complex
disorders, besides the small proportion of familial
cases with known causative mutations, are
governed by DNA variants prevalent in the general
population [16]. These variants, such as single
nucleotide polymorphisms (SNPs), tend to increase
disease risk but are insufficient to actually cause
a specific disorder. Unfortunately, a typical feature
of gene polymorphisms is their relatively weak
effect. It is therefore quite common to be confused
by conflicting results of published reports, some of
them demonstrating risk-conferring or protective
properties of a particular allele, others showing no
effect whatsoever. To overcome the potential
sources of bias discussed below, a meta-analytic
approach has been proposed. Single nucleotide
polymorphisms might not only affect the risk of
developing the disease, they may also have an
impact on particular disease phenotypes or
treatment results. The involvement of a genetic
component in BPSD aetiology seems beyond
controversy, though the exact significance of
particular polymorphisms is uncertain in the
majority of cases. Multiple genes, coding for
proteins involved in various neurotransmitter
systems, have been assessed for their putative
influence on BPSD risk. Due to significant clinical
and aetiological diversity of symptoms typically
ascribed to the BPSD construct, in research it is
usually broken down into isolated behavioural
symptoms or behavioural clusters (e.g. psychosis,
apathy, disinhibition, etc.). In the following
paragraphs the results of studies assessing the
putative contribution of genetic variants to BPSD
aetiology in AD will be reviewed.
Search strategy
PubMed and other databases accessible at our
University (Blackwell Synergy, EbscoHost, Karger,
Ovid, Proquest and Science Direct) were browsed
through using multiple queries built from words
such as Alzheimer, polymorphism, gene,
behaviour/behavioural, BPSD, and specific
behavioural symptoms, for example psychosis,
delusions, hallucinations, aggression, depression,
anxiety, etc., used in various combinations. Query
results were examined in the search for relevant
papers on BPSD genetic background. The selected
papers were then manually reviewed to look for
additional references. 
Apolipoprotein E 
The apolipoprotein E (ApoE) locus is located on
the long arm of chromosome 19. The three most
common SNPs in the APOE gene lead to changes
in the coding sequence and result in three common
isoforms of apoE: apoE2 (cys112, cys158), apoE3
(cys112, arg158), and apoE4 (arg112, arg158);
although they differ by single amino acids, these
differences profoundly alter apoE structure and
function. The apolipoprotein E plays a key role in
lipoprotein metabolism and cholesterol transport
in plasma and the nervous system. To date, it is the
only unanimously accepted genetic risk factor for
the development of sporadic AD. It has been
documented that harbouring the ε4 allele dose-
dependently increases the risk of developing AD; it
is also associated with an earlier age at onset –
subjects homozygous for ApoE ε4 almost always
develop AD by the age of 80 [17]. ApoE is a molecule
implicated in all the biochemical disturbances
characteristic of AD: β-amyloid (Aβ) aggregation,
deposition and clearance, neurofibrillary tangle
(NFT) formation, neurotoxicity, neuroinflammation,
loss of synaptic plasticity, and cholinergic
dysfunction [18].
The genetic significance of ApoE inspired
research on its potential association with theArch Med Sci 2, April / 2011 197
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psychiatric manifestations of AD – psychosis,
depression, aggression, anxiety. We have identified
37 studies evaluating this concept [19-55]. The
results of these studies are summarized in Table I. The
initial conclusion that could be drawn is the striking
inconsistency of the findings; yet this is un  -
surprising in the field of psychiatric genetics.
Regardless of the BPSD symptoms studied, the ε4
Reference No. of participants Effect of ApoE genotype on BPSD
Lehtovirta et al., 1996 [19] 58 No effect of genotype on psychosis or depression
Ramachandran et al., 1996 [20] 46 ε4 increases risk for psychosis and depression
Holmes et al., 1996 [21] 164 ε2 increases risk for depression
Holmes et al., 1997 [22] 232 ε2 increases risk for depression
Holmes et al., 1998 [23] 210 ε2 increases risk for depression and delusions
Ballard et al., 1997 [24] 51 ε4 increases risk for psychosis, lowers risk for depression
Cacabelos et al., 1997 [25] 207 No effect of genotype on behavioural disturbances
Cantillon et al., 1997 [26] 162 No effect of genotype on depression
Forsell et al., 1997 [27] 184  No effect of genotype on depression
(out of 806 studied)
Forsell et al., 1998 [28] 225  No effect of genotype on psychosis
(out of 668 studied)
Lopez et al., 1997 [29] 194 No effect of genotype on psychotic symptoms
Lyketsos et al., 1997 [30] 120 No effect of genotype on psychosis or depression
Murphy et al., 1997 [31] 77 ε4 increases risk for behavioural disturbances
Hirono et al., 1998 [32] 228 No effect of genotype on psychotic symptoms
Hirono et al., 1999 [33] 175 No effect of genotype on behavioural disturbances
Harwood et al., 1999 [34] 501 ε4 increases risk for psychosis
Levy et al., 1999 [35] 605 No effect of genotype on behavioural disturbances
Weiner et al., 1999 [36] 97 ε4 marginally associated with delusions and hallucinations
Gabryelewicz et al., 2002 [37] 139 No effect of genotype on behavioural disturbances
Scarmeas et al., 2002 [38] 87 ε4 increases risk for delusions
Sweet et al., 2002 [39] 316 Genotype does not predict time to onset of psychosis
Chang et al., 2004 [40] 135 ε4 increases risk for psychosis
Craig et al., 2004 [41] 400 ε4 increases risk for agitation/aggression
Craig et al., 2005 [42] 404 No effect of genotype on depression
Robertson et al., 2005 [43] 125 ε4 increases the level of anxiety
Borroni et al., 2006 [44] 234 No effect of genotype on psychosis
Borroni et al., 2006 [45] 232 No effect of genotype on behavioural disturbances
Craig et al., 2006 [46] 426 No effect of genotype on sleep disruption
Engelborghs et al., 2006 [47] 186 No effect of genotype on behavioural disturbances
Spalletta et al., 2006 [48] 171 ε4 increases risk for delusions
Pritchard et al., 2007 [49] 388 ε4 increases level of anxiety. No effect of genotype 
on behavioural disturbances after correction for multiple testing
Sobow et al., 2007 [50] 44 ε4 increases risk for delusions and agitation/aggression 
Zdanys et al., 2007 [51] 266 ε4 increases risk for psychosis
Borroni et al., 2009 [52] 264 No effect of genotype on depression
Grünblatt et al., 2009 [53] 72 No effect of genotype on depression
Quaranta et al., 2009 [54] 148 No effect of genotype on psychosis
Woods et al., 2009 [55] 36 ε4 increases mean behavioural scores in nursing home patients
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allele has been found to increase the risk for a given
behavioural pathology by some authors (with an
obvious notion that it might somehow be involved
in the pathogenesis of the symptoms), while others
found the ApoE genotype insignificant in this
regard. In a recent study by our group performed
in a population of carefully selected AD subjects
(very stringent inclusion and exclusion criteria to
increase the homogeneity of the participants) 
ApoE ε4 carriers had a 7-fold increased risk for
exhibiting delusions and 4.5-fold increased risk for
agitation/aggressive behaviours [50]. The potential
explanations of these discrepancies will be
discussed in a separate paragraph, as they are
largely independent of the particular polymorphism
studied.
The mechanism by which ApoE may increase the
risk for BPSD is unclear. ApoE has been shown to
promote the deposition of neuropathological
features of AD – Aβ plaques and NFTs [18]. There
are reports associating the degree of AD pathology
with behavioural symptoms, e.g. NFT burden,
particularly in the anterior cingulate, with agitation
[56] or apathy [13]. ApoE4 AD carriers show a more
profound loss in cholinergic activity in the
hippocampus and the cortex [18]; decreased
acetylcholine levels have in turn been implicated in
the pathogenesis of BPSD [10]. In neuroimaging
studies the presence of the ApoE ε4 allele was
associated with a greater rate of hippocampal,
cortical and whole-brain atrophy [57], while a link
between atrophy, hypoperfusion or hypometabolism
of various brain structures and BPSD symptoms has
repeatedly been demonstrated [58, 59].
Serotonin receptors
Genes involved in neurotransmitter systems are
usually considered one of the primary choices in
candidate-gene association studies in psychiatric
genetics, as the neurochemicals and their receptors
are also targets for treatment of psychiatric
disorders (including BPSD). Strong evidence
supports the presence of a substantial disruption
in global serotonergic neurotransmission in
dementia. In vitro and in vivo studies provide
evidence (although inconsistent) to link 5-HT
dysfunction with aggressive behaviours, psychotic
symptoms, anxiety and depression in AD [7]. The
actions of 5-HT are mediated by 14 distinct
subtypes of receptors [60]. Polymorphic variations
in serotonergic receptors have already been
implicated in the pathogenesis of many psychiatric
ailments, including schizophrenia, mood disorders,
anxiety disorders and eating disorders [61]. Two of
these receptors, 5-HT2A and 5-HT2C, have also been
examined as possible susceptibility factors for
various BPSD symptoms in AD. We have identified
11 studies evaluating the role of 5-HT2A T102C
polymorphism [62-72] and 4 studies on cys23ser
polymorphism in 5-HT2C [62, 64, 66, 71], as well as
one study on 5-HT6 [73] in the pathogenesis of
BPSD. The results of the studies are summarized in
Table II. 
Carrying the C allele of the 5-HT2A T102C SNP
was associated with psychosis [62, 63, 65, 67],
agitation [67], apathy [67], aberrant motor
behaviour [67] and depression [64], while
possession of the T allele was found to be
associated with delusions [66], agitation [66], and
depression [65]. According to the most recent of
papers, T allele carriers could also suffer from
diminished antipsychotic efficacy of second
generation antipsychotics [72]. However, 4 large
recent studies – contrary to all others – found no
significant associations of this polymorphism with
psychosis, depression, or any behavioural
disturbances [68-71] (although in the latest one,
distortions in allele frequencies were observed, with
a similar, albeit insignificant increase of the C allele
in the BPSD group [71]). No biologically plausible
explanation of the discordant findings has been
proposed as yet. T102C is a synonymous (silent)
change with no consequence for the amino acid
sequence. The gene, however, is highly polymorphic
and this polymorphism may be in linkage
disequilibrium (LD) with other SNPs in the gene –
potential true susceptibility variants – such as the
–1438 G/A promoter polymorphism or the His452Tyr
polymorphism. Some conflicting reports could stem
from different LD patterns in the evaluated cohorts.
Whilst synonymous SNPs have no direct
consequences for the protein structure, their
importance should not be discounted. The T102C
polymorphism might predispose AD patients to
various BPSD phenomena via altering gene
transcription, RNA stability, editing or splicing, or
translational efficiency, or it may influence the post-
translational modification of 5-HT2A [61]. The C allele
of the T102C variation seems to be associated with
reduced 5-HT2A receptor densities in brain tissues
(the temporal cortex in particular) [74], a finding
typical for AD itself as well. This could lead to worse
dopaminergic modulation mediated by the
serotonergic system and – taken together with the
dopaminergic hypothesis of psychosis – might
putatively be responsible for the association of this
genetic variant with the psychotic spectrum [75].
The serine allele of the cys23ser polymorphism
of the 5-HT2C gene has previously been found to be
associated with hallucinations [62], hyperphagia (in
females only) [62], and depression [64]. In the most
recent study by Pritchard et al., the same C allele
was significantly associated with anxiety in females;
however, the effects of C allele-containing
genotypes (CC and GC) did not reach statistical
significance [71]. 5-HT2C is one of the pivotalArch Med Sci 2, April / 2011 199
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serotonin receptors highly expressed in multiple
brain areas. On a general level it is one of the key
elements of the serotonergic inhibitory modulation
of the dopaminergic tone, playing a crucial role in
a wide range of psychiatric disorders, as diverse as
eating disorders, anxiety and mood disorders
(which could provide a rationale for the
aforementioned results of AD-BPSD studies), and
addiction, as well as influencing antipsychotic
efficacy and side effects [76]. Unfortunately, the
biological relevance of 5-HT2C for psychiatric pheno  -
types is contradictory to the poor, inconsistent
results obtained by genetic investigations. Apart
from the incomplete coverage of the gene, with 
the above described possibility of an LD with yet
undiscovered pathogenetically influential SNPs, and
some universal pitfalls described in detail in a later
paragraph, there are other intriguing confounding
factors unique to the 5-HT2C gene and receptor
protein, often called “the fine-tuning machinery”.
These include the modulatory influences of 5-HT2C-
expressing glutamatergic and GABAergic inter  -
neurons exerting regionally specific, frequently
different actions, as well as complicated 5-HT2C
receptor mRNA editing patterns that can modify its
affinity for the binding of serotonin and its
efficiency to activate the second messenger
cascade [77]. Via a specific editing profile the
machinery will probably counteract the effects of
genetic variations – more efficiently in some
subjects, completely blunting the genetic
background, reducing the penetrance of mutations,
and making most investigations underpowered, but
less efficiently in other subjects, to the point that
the variation in the HTR2C turns out to be
sufficiently relevant to be associated with
a psychiatric disorder [76].
Serotonin transporter
The 5-HT transporter (5-HTT) is central to the
control of brain 5-HT neurotransmission by
regulating the magnitude and duration of the
serotonergic response through the reuptake of 
5-HT at the synapse. Furthermore, 5-HTT is a target
for several types of pharmacological interventions
in psychiatric disorders (e.g. SSRIs). Investigations
of possible associations between 5-HTT and BPSD
have produced inconsistent findings. Two different
variable number tandem repeats (VNTR)
polymorphisms in the SERT  gene (located on
chromosome 17q) have been examined in this
context; the results are summarized in Table III. 
Reference No. of participants Effect of 5-HT receptor genotype on BPSD
5-HT2A receptors (T102C polymorphism)
Holmes et al., 1998 [62] 211 C allele increases risk for hallucinations
Nacmias et al., 2001 [63] 275 CC genotype and C allele increase risk for psychosis
Holmes et al., 2003 [64] 158 CC and TT genotypes increase risk for depression
Rocchi et al., 2003 [65] 135 CC genotype increases risk for psychosis
Assal et al., 2004 [66] 96 T allele increases risk for delusions and agitation/aggression
Wa Lam et al., 2004 [67] 87 CC genotype increases risk for delusions, agitation, 
apathy and aberrant motor behaviour
Micheli et al., 2006 [68] 208 No effect of genotype on depression
Craig et al., 2007 [69] 406 No effect of genotype on psychosis
Wilkosz et al., 2007 [70] 324 No effect of genotype on time to psychosis onset or depression
Pritchard et al., 2008 [71] 393 No effect of genotype on behavioural disturbances 
(increase in CC genotype and C allele in psychosis, not significant)
Angelucci et al., 2009 [72] 80 T allele increases risk for delusions and treatment-resistance 
to second generation antipsychotics
5-HT2C receptors (cys23ser polymorphism)
Holmes et al., 1998 [62] 211 C allele increases risk for hallucinations and hyperphagia (in females)
Holmes et al., 2003 [64] 158 CC genotype increases risk for depression
Assal et al., 2004 [66] 96 No effect of genotype on behavioural disturbances
Pritchard et al., 2008 [71] 394 C allele increases risk for anxiety in females
5-HT6 receptors
Liu et al., 2001 [73] 145 No effect of genotype on depression
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Firstly, there is a functional polymorphism in the
5-HTT gene-linked polymorphic region (5-HTTLPR);
the long (L) and short (S) alleles are defined by
differing numbers of a 44-base pair repetitive
sequence. The homozygous S/S genotype has been
associated with an increased risk of unipolar and
bipolar depression, anxiety, substance abuse, and
a predisposition to suicide or depression following
stressful life events [78]. Conversely, the homo  -
zygous L/L genotype was associated with
a predisposition to obsessive-compulsive disorder
(OCD) and increased intensity of hallucinations in
individuals with schizophrenia [78]. In AD, 5-HTTLPR
polymorphism has been evaluated in 14 studies [44,
45, 53, 54, 65, 66, 68, 79-85]. Eight of them proved
negative, finding no association whatsoever. Even
in the remaining six, the results are conflicting. Four
papers, in accordance with the preclinical BPSD
aetiological hypotheses suggesting a lower level of
synaptic 5-HT, demonstrated a detrimental effect
of the L allele on aggression, psychosis, and
irritability in AD patients [54, 80, 81, 83]. In one of
the studies, however, the result did not remain
significant after correction for multiple testing [83].
The putative association between 5-HT depletion
and psychosis could further be strengthened by the
demonstrated efficacy of a selectively serotonergic
antidepressant – citalopram – in the treatment of
psychotic disturbances in demented individuals
[86]. In contrast, Borroni et al. in 2 other studies
observed an association between the S allele and
SS genotype with psychotic symptoms in AD, and
a protective effect of the LL genotype against
“psychotic” endophenotype (described above) [44,
45]. The authors provide no attempt to explain
these observations on a biological basis. However,
in a recent meta-analysis, the S allele carriers
demonstrated significantly greater amygdala
activation in response to neutral environmental
stimuli when compared to the L allele harbouring
subjects, providing an indirect clue for the
comprehension of the S allele’s involvement in
BPSD pathogenesis [87].
The numerous studies aiming to reveal
associations between polymorphisms in the 5-HTT
gene and various behavioural traits are based on
the assumption that these polymorphisms, or
polymorphisms linked to them, influence the
Reference No. of participants Effect of 5-HT transporter genotype on BPSD
LPR (linked polymorphic region)
Li et al., 1997 [79] 196 No effect of genotype on depression
Sukonick et al., 2001 [80] 137 L allele and LL/LS genotypes increase risk for aggression
Sweet et al., 2001 [81] 332 L allele and LL/LS genotypes increase risk for psychosis and aggression
Rocchi et al., 2003 [65] 135 No effect of genotype on psychosis
Assal et al., 2004 [66] 96 No effect of genotype on behavioural disturbances
Ha et al., 2005 [82] 65 No effect of genotype on delusions and aggression
Borroni et al., 2006 [44] 234 SS genotype and S allele increase risk for psychosis
Borroni et al.2006 [45] 232 LL genotype decreases risk for “psychosis” endophenotype
Micheli et al., 2006 [68] 208 No effect of genotype on depression
Pritchard et al., 2007 [83] 367 L allele increases risk for irritability. No effect of genotype 
on behavioural disturbances after correction for multiple testing
Ueki et al., 2007 [84] 200 No effect of genotype on behavioural disturbances
Albani et al., 2009 [85] 235 No effect of genotype on behavioural disturbances
Grünblatt et al., 2009 [53] 72 No effect of genotype on depression
Quaranta et al., 2009 [54] 148 L allele increases risk for psychosis 
in a dose-dependent fashion
STin2 VNTR (variable number of tandem repeats)
Li et al., 1997 [79] 196 12-repeat allele non-significantly (p = 0.07) associated with depression
Assal et al., 2004 [66] 96 No effect of genotype on behavioural disturbances
Pritchard et al., 2007 [83] 367 10-repeat allele increases risk for psychosis. 
No effect of genotype after correction for multiple testing
Ueki et al., 2007 [84] 200 10-repeat allele increases risk for behavioural disturbances 
and aggression
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binding capacity or function of 5-HTT in the human
brain. However, some recent studies exploring
a possible association between polymorphisms in
SERT and the expression of 5-HTT protein or 5-HT
binding in the brains of healthy controls or patients
did not reveal any genotype-dependent differences,
blurring the “classic”, coherent picture [78, 88].
Drawing conclusions is further complicated by
studies on other SNPs within the gene, verifying
the existence of subgroups within the dichotomous
S/L paradigm, for example converting the activity
associated with the L allele to that expected for the
S allele [89]. Considering the 5-HTTLPR poly  -
morphism as tri-allelic possibly alters the
interpretations of previous association studies
based on a simple “L vs S” dichotomy model.
Another confounding factor potentially leading to
non-replication of  results may be a failure to control
for epistatic effects. The SERT gene is a classical
example of the necessity to control for gene-
environment interactions, with numerous studies
consistently proving that exposure to adverse life
events strengthens the association between 
5-HTTLPR and a given behavioural phenotype
(particularly depression- and anxiety-related) [90]. 
Another functional polymorphism studied was
the VNTR in intron 2 of the 5-HTT gene comprising
9, 10 or 12 copies of a 16/17-base pair element
(frequently termed STin2.9, STin2.10 and STin2.12
VNTR, respectively). Association studies have linked
this polymorphism to several behavioural phe  -
notypes (as well as antidepressant efficacy),
although without consistency [78]. Only 4 research
groups have evaluated the significance of STin2
VNTR polymorphism in BPSD in AD [66, 79, 83, 84].
Two of the studies were negative, while in the other
two STin2.10 was associated with aggression,
psychosis and the total level of behavioural
psychopathology (one of those insignificant after
correction for multiple testing). The STin2 VNTR
displays functionality both in vitro and in vivo [78,
88]. In expression studies, the 12-repeat allele was
found to be a stronger enhancer of transcriptional
activity than the 10-repeat allele. Moreover, apart
from the number, the primary structure of the
repeats could also affect the transcription of the
gene. In transgenic mice, STin2 VNTR genotype was
demonstrated to exert an important regulatory role
in development of the serotonergic system.
Transient alterations in fetal 5-HT homeostasis can
modify the wiring of brain connections leading to
permanent changes in adult behaviour. It is
therefore possible that the effects of both 5-HTT
polymorphisms are more pronounced during
embryogenesis and development [91]. 
Catechol-O-methyltransferase 
The catechol-O-methyltransferase (COMT) gene
is a major enzyme in synaptic DA catabolism with
a critical role in the prefrontal cortex because of the
relative lack of DA transporters in this region. It
contains a functional common polymorphism
characterized by G to A transition at codon 108/158
(soluble/membrane-bound COMT) resulting in
a valine-to-methionine substitution, giving rise to
a significant, three-to-fourfold reduction in its
enzymatic activity. The presence of valine (H allele
= high activity) in the coding sequence corresponds
dose-dependently with reduced prefrontal DA levels,
subsequently leading to the upregulation of striatal
dopamine activity (via increased tyrosine
hydroxylase expression, the rate-limiting enzyme
in DA synthesis) [92]. This reciprocal association
could therefore explain both poorer cognitive scores
(lower prefrontal DA) and an increased risk for
schizophrenia (higher midbrain DA) [93] in COMT
Val158 carriers [94]. The role of COMT genetic
variants as BPSD risk modifiers has been analysed
in five published papers [44, 45, 95-97], four of
which were conducted by Borroni et al. The
Met158Val polymorphism was evaluated either
separately or as part of a four-loci haplotype.
Contrary to other genes evaluated in AD
behavioural genetics the results on the role of
COMT are convergent in demonstrating the
COMT*H genotype as a culprit implicated in the
aetiology of psychosis in AD (however, the studies
by Borroni et al. evaluate – at least in part – the
same population, although in various aspects). The
Reference No. of participants Effect of COMT genotype on BPSD
Borroni et al., 2004 [95] 181 HH genotype and H allele increase risk for psychosis
Sweet et al., 2005 [96] 373 A four-locus haplotype increases the risk for psychosis
Borroni et al., 2006 [44] 234 HH genotype and H allele increase risk for psychosis
Borroni et al., 2006 [45] 232 HH genotype and H allele decrease risk for “frontal” 
endophenotype and increase risk for hallucinations
Borroni et al., 2007 [97] 246 HH genotype and H allele increase risk for psychosis. 
Alleles at four loci (haplotype) interact to influence psychosis risk
Table IV. Studies on the association between catechol-O-methyltransferase (COMT) genotype and BPSD in AD (positive
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relevance of the HH genotype or H allele for AD
psychosis has been observed both in isolation [44,
45, 95] and in interaction with three other loci
forming a haplotype [96, 97]. Furthermore, in one
of the studies COMT*H decreased the risk for
disinhibition and euphoria grouped together as
a “frontal” endophenotype. The susceptibility to
a cognitively impaired/psychotic phenotype in
COMT 158Val carriers might be explained by the
above described modulating role of COMT in DA
metabolism with a genotype-dependent inverse
balance in striatal/frontal DA activity regulation.
This mechanism is of course not restricted to
schizophrenia alone, possibly translating into
a universally increased proneness to psychosis and
cognitive decline, both crucial aspects of a psychotic
AD phenotype. However, one has to bear in mind
that the reported associations between COMT
Met158Val and cognition or psychosis were
relatively weak (or even inconsistent on a meta-
analytic level [98]); therefore – despite a uniform
correlation pattern in AD-BPSD studies – the
aetiological significance of this polymorphism alone
should not be overestimated. 
Dopamine receptors and transporter
The dopaminergic system plays a role in many
aspects of human behaviour, including aggression,
psychosis, depression, elation and the control of
movement. The action of DA is mediated by five
distinct receptor subtypes, DRD1-DRD5, and the
dopamine transporter (DAT). Dopamine receptors
are major targets for antipsychotic agents, one of
the most important classes of medications used in
the treatment of BPSD, and for drugs of abuse
eliciting behavioural and psychological changes.
Polymorphisms in DRD1-DRD4 and DAT have been
evaluated in various psychiatric disorders, typically
with mixed results [99]. Contrary to primarily
psychotic disorders, the development of psychotic
symptoms in AD does not appear to be associated
with brain or plasma concentrations of dopamine
or its metabolites (homovanillic acid). Nevertheless,
the effects of dopamine in the synapse are
dependent not only on its concentrations, but also
on receptor densities (as well as post-receptor
signal transduction mechanisms). Accordingly,
striatal DRD2 and DRD3 availability has recently
been proven to increase in AD patients with
delusions [100]. The variants DRD1 (A-48G), DRD2
(ser311cys), DRD3 (ser9gly), DRD4 (VNTR) and DAT
(3’-UTR) have been investigated in 7 studies on
BPSD [8, 53, 101-105], as usual with contradictory
results (summarized in Table V). DRD1 A allele,
either in homo- (A/A) [8] or heterozygosity (A/G)
[101], was found to be associated with psychosis
and aggression [8] or aggression and hallucinations
(but not delusions) [101]. However, in the latest and
largest study, the DRD1 genotype did not correlate
with behavioural disturbances [103]. The
inconsistent direction of effect suggests spurious
associations or LD of the A-48G variant with a true
susceptibility factor. Investigations on DRD2
demonstrated no associations of the ser311cys
polymorphism with any behavioural symptom [8,
103]. Results on the hypothetically most relevant
DRD3 ser9gly variant are conflicting. All possible
variants – Ser/Ser or Gly/Gly homozygosity, Ser/Ser
genotype, or possession of Gly allele – have been
postulated to play a role in the aetiology of
delusions or psychosis [8, 101, 104]. However, in
other studies DRD3 showed no association with
psychosis risk whatsoever [102, 103]. In another
recent study ser9gly homozygosity increased the
risk for elation [103], although the result did not
remain significant after multiple testing. The
discordance of the findings might suggest that the
observed associations were accidental. For the same
reason, the DRD4 VNTR polymorphism seems to
play a minor (if any) role in BPSD pathogenesis [8,
53, 103]. DAT1 3’UTR variants were tested in AD
patients in a single study, with the 9-repeat allele
increasing risk for irritability, while the 10-repeat
allele showed an association with aberrant motor
behaviour [105]. However, 9- and 10-repeat alleles
made up > 97% of all the observed alleles and
significance was lost after Bonferroni correction
[105].  
Other genes 
The significance of several other genes has been
assessed in single studies. Their detailed analysis
is hardly available due to editorial constraints. Two
research groups tested the hypothesis that
interleukin-1β (IL-1β) might act as a BPSD modifier
gene. Craig et al. found an association between the
CC genotype or C allele (responsible for the
diminished production of IL-1β) with both delusions
and hallucinations in AD patients [106], while
McCulley et al. associated depressive symptoms
with the possession of a T allele, thus with raised
IL-1β levels [107]. To establish a possible relationship
between oxidative stress and the non-cognitive
symptoms of AD, polymorphic sites in genes coding
for heat-shock proteins (HSP) and glutathione-S-
transferases (GST) have been evaluated in AD
subjects [108, 109]. Clarimon et al. reported an allele
dose-dependent increase in NPI-measured level of
behavioural pathology in carriers of the A2 allele of
the HSPA1B gene (involved in the stress response)
[108]. Spalletta et al. observed an association
between genetic variants in the GST polymorphic
sites and AD age of onset or rate of progression;
however, no effect of GST polymorphisms on
behavioural symptom severity was found [109].
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candidate genes Craig et al. in two separate studies
tested the significance of polymorphisms in
tryptophan hydroxylase (TPH) and monoamine
oxidase-A genes in relation to AD behavioural
pathology [46, 110]. The TPH is the rate-limiting
enzyme in the biosynthesis of serotonin catalyzing
the conversion of tryptophan to 5-HT. It was
observed that male AD participants with a history
of agitation/aggression were significantly more
likely to possess C allele-containing genotypes [110].
In another paper, the authors hypothesized that the
risk of sleep disturbance in AD may, at least in part,
be influenced by the availability of serotonin used
for melatonin synthesis secondary to MAO-A VNTR
polymorphic variation. A quantitative sleep
disturbance score was significantly higher in the
patients possessing MAO-A 4-repeat allele
genotypes [46]. Go et al. evaluated the significance
of neuregulin-1 (NRG1) SNP in conferring extra risk
for psychotic symptoms in AD [111]. There is strong
evidence from several studies that genetic variation
in NRG1 has a substantial impact on schizophrenia
risk. Genetic linkage studies in patients with AD
with psychosis revealed multiple suggestive peaks,
including 8p, within the chromosomal region of
NRG1. Go et al. observed an association between
NRG1 SNP, both in isolation and as part of a 3-loci
haplotype, and a psychotic phenotype in AD [111].
Another effort to dissect the genetic background
of BPSD focused on the IDE gene coding for insulin-
degrading enzyme protein [112]. The IDE plays a key
role in degrading several important peptides,
including Aβ. A correlation was observed between
carrying the C allele of the IDE gene and the risk for
affective disturbances in AD, with no effect on other
behavioural symptoms [112]. 
Reference No. of  Studied gene  Effect of genotype on BPSD
participants
Sweet et al., 1998 [8] 275 DRD1, DRD1 A/A genotype increases risk for psychosis
DRD2, and aggression in whites.
DRD3, DRD3 homozygosity (Ser/Ser or Gly/Gly) increases risk 
DRD4 for psychosis in whites.
No effect of DRD3 genotype on aggression.
No effect of DRD2 or DRD4 genotypes on psychosis 
or aggression
Holmes et al., 2001 [101] 134 DRD1,  DRD1 A/G genotype increases risk 
DRD3 for aggression and hallucinations. 
No effect of DRD1 on delusions.
DRD3 Ser/Ser genotype increases risk 
for delusions compared with Gly/Gly. 
No effect of DRD3 on aggression or hallucinations
Craig et al., 2004 [102] 416 DRD3 No effect of genotype on psychosis
Grünblatt et al., 2009 [53] 72 DRD4 No effect of genotype on depression
Pritchard et al., 2009 [103] 395 DRD1,  DRD3 homozygosity (Ser/Ser or Gly/Gly) 
DRD2, increases risk for elation. DRD4 7-repeat allele 
DRD3, increases risk for agitation/aggression, 
DRD4 decreases risk for depression. 
DRD4 4-repeat allele increases risk for depression, 
decreases risk for agitation/aggression. 
No effect of genotype after correction 
for multiple testing. No effect of genotype on psychosis.
No effect of DRD1 or DRD2 genotypes on 
behavioural disturbances
Sato et al., 2009 [104] 210 DRD3 DRD3 Gly allele increases risk for delusions. 
No effect of DRD3 on other behavioural disturbances 
Pritchard et al., 2008 [105] 395 DAT 9-repeat allele increases risk for irritability. 
10-repeat allele increases risk for aberrant 
motor behaviour. No effect of genotype after 
correction for multiple testing. 
No association observed for psychosis, 
depression, agitation/aggression
Table V. Studies on the association between dopamine receptors and dopamine transporter genotypes and BPSD
in AD (positive results in bold) 
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In the most recent study an association between
brain-derived neurotrophic factor (BDNF) genetic
variants and depression in AD was evaluated [52].
Brain-derived neurotrophic factor is an important
regulator of neuronal plasticity and survival.
A functional Val66Met SNP in the coding region of
the BDNF gene (located on chromosome 11p14) has
previously been associated with major depression,
geriatric depression, and the risk of AD itself,
although with conflicting results. In their 
study, Borroni et al. observed a dose-dependent
correlation between presence of the A allele (coding
for methionine) and the risk of depression comorbid
with AD [52]. 
Potential sources of between-study variations
One of the major obstacles in the field of
psychiatric genetics concerns problems with the
consistency of the results, which obviously hinders
their interpretation considerably. Typical associa  -
tion studies test the significance of given poly  -
morphisms as risk-conferring or protective factors
for a specific disorder in a case-control manner. An
important drawback inherent to this strategy is the
recruitment process solely based on clinical
diagnoses (phenotypes). As complex (multifactorial)
disorders suffer from both genetic and phenotypic
heterogeneity, simply relying on the ICD-10- or
DSM-IV-based symptomatic, biologically undeter  -
mined criteria will frequently obscure the genetic
signals. In the field of neurodegenerative disorders
even accurate application of the criteria leaves some
space for uncertainty. Subjects asymptomatic
during the interview might have been developing
brain pathology for several years, though the clinical
symptoms threshold had not yet been reached; the
differential diagnosis of dementia without autopsy
confirmation can be a source of substantial
difficulties as well. In this regard it is beneficial to
remember that the same symptoms can have
completely diverse pathogenetic backgrounds in
different dementing disorders. This applies to the
genetic studies as well, e.g. in a study by
Engelborghs et al. ApoE genotype had no effect on
BPSD in AD subjects, in frontotemporal dementia
(FTD) patients, however, a dose-dependent effect
of the ε4 allele on aggressiveness and the total level
of behavioural pathology was identified [47].
Several means of circumventing the issue are
usually considered, one of which is substituting
diagnoses with endophenotypes – traits biologically
and genetically simpler, mediating between
susceptibility genes and full expression of the
disorder. The studies on AD behavioural genetics
follow this line of thought, narrowing the entire
phenotype to patients with comorbid behavioural
abnormalities, symptom clusters or finally isolated
symptoms. Unfortunately, as can be seen from the
aforementioned results, the clarity and consistency
of the findings did not improve much, still not
allowing for firm conclusions. Several sources of
such ongoing disparity can be taken into
consideration.
Variability in general study design
The BPSD symptoms are rarely very stable
phenomena in AD patients. Notwithstanding the
general impression that the overall level of
Reference No. of  Studied gene Effect of genotype on BPSD
participants
Craig et al., 2004 [106] 406 CC genotype and C allele increase risk for psychosis
McCulley et al., 2005 [107] 133 T allele increases risk for depression
Clarimon et al., 2003 [108] 77 HSP70-2  A2 allele increases risk for behavioural 
(HSPA1B) disturbances in a dose-dependent fashion
Craig et al., 2004 [110] 396 TPH CC genotype and C allele increase aggression
Go et al., 2005 [111] NRG1 NRG1 SNP increases the risk for psychosis.
A 3-SNP haplotype with NRG1 increases 
the risk for psychosis
Craig et al., 2006 [46] 426 MAO-A 4-repeat allele increases risk for sleep disruption
Spalletta et al., 2007 [109] 99 GST No effect of genotype on behavioural disturbances
Sato et al., 2008 [112] 207 IDE C allele increases risk for “affective disturbances”.
No association with other behavioural symptoms
Borroni et al., 2009 [113] 264 BDNF A (Met) allele increases risk 
for depression in a dose-dependent fashion
Table VI. Other studies on behavioural genetics in AD (positive results in bold)
GST – glutathione S-transferase, HSP – heat shock protein, IL-1β – interleukin 1β, MAO-A – monoamine oxidase A, NRG – neuregulin, 
SNP – single nucleotide polymorphism, TPH – tryptophan hydroxylase
IL-1β promoter
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psychopathology increases with dementia severity,
they have a tendency to wax and wane, their
severity fluctuating with time. Not surprisingly, the
results of genetic studies will therefore heavily rely
on the average disease stage of the AD participants.
In a recent study on ApoE and psychosis in AD,
Zdanys et al. found that the ε4 detrimental effect
was statistically significant only for the severe-stage
patients [51], a result already seen in some [34] but
not all [37] studies. Consequently, an association
can be missed if mild-to-moderate stage patients
predominate [33, 35]. A significant choice in this
context is that of a cross-sectional versus
longitudinal study design. Cross-sectional studies
can omit episodes that occur outside the
assessment period. If patients are being followed
over a period of time, a higher frequency of
symptoms can be detected, significantly influencing
the attribution of patients to predefined study
groups. 
Diagnostic criteria employed
A variety of methods have been used by the
researchers to identify behavioural abnormalities
in AD participants. Some older studies relied only
on general clinical examination and descriptive
assessments, while others used rating scales, or
a combination. However, even with rating scales it
is difficult to reconcile contradictory reports due to
a wide range of scales having been used for any
symptom. Some diagnostic tools assess the
symptoms qualitatively (simply defining the
presence or absence of a given BPSD symptom),
while others provide quantitative measures (e.g.
the popular Neuropsychiatric Inventory – NPI),
permitting the choice of different thresholds of
severity and allowing for the inclusion of patients
only with clinically significant psychopathology. 
Choice of symptoms
The range of symptoms evaluated has to be
precisely defined, e.g. in the papers one can find
“psychosis”, delusions and hallucinations analysed
together or separately, or persecutory delusions on
their own. In most cases AD patients exhibit more
than one behavioural symptom. The isolated
symptoms are frequently interrelated, e.g. the
presence of delusions could likely be associated
with hallucinations, agitation/aggression or sleep
disturbances, while depression could increase the
chance of comorbid anxiety, sleep and appetite
disturbances. This constitutes one of the major
limitations for the correct evaluation of BPSD
pathogenesis. Therefore, some of the authors
propose using clusters of symptoms – behavioural
endophenotypes – supposedly linked to specific
neurotransmitter abnormalities or even sharing
a common genetic basis [45]. In one of the studies
carrying the COMT*H allele was not significantly
correlated with a “psychotic” phenotype (defined
as NPI items delusions + hallucinations + night-time
disturbances), but proved to be significantly
associated with hallucinations alone [45]. Two
different approaches may thus be considered –
relating the polymorphic variations to isolated
symptoms or symptom clusters. 
Selection bias 
Apart from the clinical characteristics of the
investigated population, the results of genetic
studies can heavily depend on its ethnicity or even
its genetic homogeneity within one race. Some
populations are considered genetically homo  -
geneous, e.g. Northern Ireland inhabitants or
Sephardic Jews. This increases the consistency of
the findings. Such populations, however, are prone
to the founder effect (loss of genetic variation due
to shared ancestry). Selection bias can also
manifest itself through the choice of setting for
patient recruitment: nursing home dwellers,
inpatients or patients treated in an ambulatory
setting. The most inclusive population-based
studies recruit “real-life” patients, making the
results much more practical, although at a price of
numerous medical, environmental, and drug-related
confounders, particularly troublesome in genetic
studies.
Statistical power
Commonly, the problem with divergent findings
of genetic studies lies with inadequate statistical
power owing to an insufficient number of study
participants. More studies on larger cohorts with
appropriate assessment tools as well as using
a meta-analytic approach are potential solutions to
overcome the problem.
Another issue worth mentioning in the context
of statistical methods is the correction for multiple
testing. Some of the observed associations might
be spurious as the majority of studies are subject
to considerable multiple testing. Employing proper
statistical methods can nullify an initially statis  -
tically significant result [49].
Carrier status versus dose
Interpretation of genetic studies requires even
more caution as some authors evaluate genetic
associations dichotomously (carrier vs non-carrier
status of a particular allele) [51], while others
examine the effect of allele “dose” in relation to
BPSD symptoms [38]. Sometimes only a homo  -
zygous genotype for a particular allele increases
BPSD risk [67]; in other cases it is only the carrier
status that matters [63].206 Arch Med Sci 2, April / 2011
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Inherent limitations of genetic studies
Genetic studies on complex traits are prone to
several limitations. One has to remember that the
aetiology of BPSD is multifactorial, with an interplay
of genetic, other biological, environmental and
social factors, the individual influence of which is
rather difficult to disentangle. Multiple genes are
usually involved in the pathogenesis of a complex
trait, often with a contradictory effect (susceptibility
genes, protective genes, modifying genes);
moreover, the effects of individual polymorphisms
are usually weak, requiring large cohorts to
demonstrate. Some of the SNPs are statistically
associated with each other in the form of
a haplotype increasing the complexity of epistatic
(gene-gene) interactions. The discrepant findings
might also relate to the fact that some of the
polymorphisms studied are not true risk factors
themselves but only represent markers located near
some unidentified genes associated with AD or
BPSD. Importantly, drawing final conclusions and
comparing association results is often hampered
as genes usually contain many polymorphic sites,
whereas the majority of studies only offer analyses
of single polymorphisms, sometimes different ones
in successive studies (it should be noted that
testing all polymorphisms present in a particular
gene of interest is usually unfeasible for practical
reasons). 
Conclusions
The last couple of years have witnessed an
unprecedented struggle in the search for the
genetic correlates of behavioural symptoms in AD.
The strategy of narrowing the studied phenotype
to clinically – and hopefully genetically – distinct
and homogeneous populations has been becoming
increasingly popular as a way to circumvent typical
problems of psychiatric genetics (or genetics of
most complex traits, more generally speaking). The
results of this tactic have been and still are awaited
with ongoing expectations. Unfortunately, as one
can see from this review, definite answers are
hardly available. The reports still mainly fuel
discussions on the potential sources of discre  -
pancies rather than providing a stimulus for finding
practical applications of purely scientific ob  -
servations. Such a gloomy perspective could,
however, derive from unrealistic expectations. The
influence of genetic polymorphisms on BPSD profile
might simply be weak enough to suffer from
a particular vulnerability to potential confounders,
so difficult to control for in genetic association
studies, or simply lack of adequate statistical power.
Another explanation, not mutually exclusive with
the former, could focus our attention on the still
limited technical possibilities and their rapid
evolution in recent years. With whole-genome
scans, the use of microarrays and chips allowing
a simultaneous study of thousands of genes and
their interactions, and an increasing awareness of
the significance of haplotypes, rather than isolated
SNPs, the perspectives of genetics should probably
be sketched in brighter colours. Finally, interpreting
the outcome of genetic research separately from
neurochemical, neuropathological, neuroimaging
or electrophysiological studies seems an undesired
oversimplification. Fusing the available multi  -
disciplinary data can result in discoveries important
also in practical terms. Probably the most import  -
ant lesson from studies on BPSD is that the
pathogenesis of the same symptoms (e.g.,
psychotic or depressive) can be totally divergent in
different psychiatric disorders, e.g. the biological
basis for the psychotic symptoms in AD seems to
be more closely associated with cholinergic-
serotonergic imbalance than with dopamine,
traditionally given priority in schizophrenia
neurobiology. The same is true even for various
types of dementia, albeit more closely related at
first glance. It is therefore unwise to mechanically
project knowledge on “general” psychiatry to
neuropsychiatry, on one type of dementia to
another, or to rely solely on atheoretical, strictly
symptomatic classifications in neurobiological
research. From this point on, only one step
separates us from translating those conclusions
into highly expected, pharmacological applications.
One should bear in mind that this has already
happened, as in the previously cited study by
Pollock  et al. on the efficacy of serotonergic
citalopram in the treatment of psychosis in AD [86],
or in a study of the 5-HT agonist tandospirone
effective in reducing agitation/aggression, irritability,
anxiety and depression in AD patients [113]. 
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